Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Verified date | July 2023 |
Source | NKGen Biotech, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
Status | Terminated |
Enrollment | 11 |
Est. completion date | September 21, 2023 |
Est. primary completion date | September 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Capable of giving signed informed consent 2. Males and females age = 18 years 3. Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic EGFR-positive malignancy for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator. 4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort). 5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below: 1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received = 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody. 2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received = 1 prior lines of therapy for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/PD-L1 antibody. 3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received = 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody. 6. One or more measurable tumors lesions per RECIST v1.1 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. Adequate bone marrow, hepatic and renal function. Key Exclusion Criteria: 1. Superior vena cava syndrome contra-indicating hydration 2. Untreated or symptomatic central nervous system (CNS) metastases 3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade = 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia) 4. Treatment with systemic anticancer therapy or an investigational device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment. 5. Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade > 1) toxicity from previous radiotherapy 6. Clinically significant cardiovascular disease 7. Major surgery within 4 weeks prior to any study treatment administration 8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol 9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment. 10. Known history of testing positive for human immunodeficiency virus (HIV), and/or positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection. 11. Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring systemic immunosuppressive therapy 12. A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor 13. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
United States | USC/Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Sarcoma Oncology Center | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
NKGen Biotech, Inc. | Affimed GmbH |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1/Dose Escalation | Determine the maximum tolerated dose (MTD) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period. | 28 days starting on cycle 1 day 1 | |
Primary | Phase 1/Dose Escalation | Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01.
To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period. |
28 days starting on cycle 1 day 1 | |
Primary | Phase 2a/Expansion | Determine objective response rate (ORR) of AFM24 in combination with SNK01. Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 | Up to 24 months | |
Secondary | Phase 1/Dose Escalation | Assess safety and tolerability of AFM24 in combination with SNK01. Determine frequency and severity of treatment-emergent AEs (TEAEs) per National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI CTCAE v 5.0). | Up to 24 months | |
Secondary | Phase 1/Dose Escalation | Determine preliminary efficacy of AFM24 in combination with SNK01. Determine ORR using RECIST v1.1 evaluated by local assessment. | Up to 24 months | |
Secondary | Phase 1/Dose Escalation | Maximum observed plasma concentration (Cmax) of AFM24 | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 1/Dose Escalation | Time to maximum plasma concentration (Tmax) of AFM24 | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 1/Dose Escalation | Minimum plasma concentration (Cmin) of AFM24 | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 1/Dose Escalation | Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24 | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 1/Dose Escalation | Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 anti drug antibodies (ADAs) through completion of the Phase 1/dose escalation portion | Up to 24 months | |
Secondary | Phase 2a/Expansion | Safety and tolerability of AFM24 in combination with SNK01 Frequency of TEAEs graded according to NCI CTCAE v 5.0 | Up to 24 months | |
Secondary | Phase 2a/Expansion | To assess progression-free survival (PFS) according to RECIST v1.1 by local assessment Assess the number of subjects with PFS defined as duration of time from start of combination treatment to date of progression. | Up to 24 months | |
Secondary | Phase 2a/Expansion | To assess overall survival (OS). | Up to 24 months | |
Secondary | Phase 2a/Expansion | To assess duration of response (DOR) according to RECIST v1.1 by local assessment. | Up to 24 months | |
Secondary | Phase 2a/Expansion | To assess clinical benefit rate (CBR) according to RECIST v1.1 by local assessment. | Up to 24 months | |
Secondary | Phase 2a/Expansion | Maximum observed plasma concentration (Cmax) of AFM24. | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 2a/Expansion | Time to maximum plasma concentration (Tmax) of AFM24. | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 2a/Expansion | Minimum plasma concentration (Cmin) of AFM24. | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 2a/Expansion | Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24. | 28 days starting on cycle 1 day 1 | |
Secondary | Phase 2a/Expansion | Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 ADAs and frequency of subjects developing neutralizing ADAs. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |